Welcome to our dedicated page for Arrivent Biopharma news (Ticker: AVBP), a resource for investors and traders seeking the latest updates and insights on Arrivent Biopharma stock.
ArriVent BioPharma, Inc. reports news as a clinical-stage biopharmaceutical company developing oncology therapeutics. Company updates center on firmonertinib, an EGFR inhibitor for EGFR mutant non-small cell lung cancer, including exon 20 insertion and PACC mutation settings, as well as regulatory designations, clinical data presentations, and global study activity.
Recurring developments also cover ArriVent's antibody-drug conjugate portfolio, including ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies, and ARR-002, a MUC16/NaPi2b targeting tetravalent ADC with an initial focus in ovarian and endometrial cancers. News releases also include IND clearances, oncology conference presentations, financial results, collaborations, and executive or commercial organization updates.
ArriVent BioPharma (Nasdaq: AVBP) reported first quarter 2026 results and pipeline progress. Cash and investments were $326.4 million as of March 31, 2026, expected to fund operations into 4Q 2027. Net loss was $43.3 million, with R&D expenses of $37.6 million and G&A of $8.5 million.
ArriVent highlighted pivotal Phase 3 firmonertinib programs in EGFR-mutant NSCLC, including expected topline FURVENT data in mid-2026 and China NMPA accelerated approval in second-line EGFR exon 20 insertion NSCLC. ARR-217 and dual-target ADC ARR-002 advanced via FDA IND clearances, with first patient dosing for ARR-002 targeted for 2H 2026.
ArriVent (Nasdaq: AVBP) announced FDA IND clearance for ARR-002, a tetravalent MUC16/NaPi2b-targeting antibody-drug conjugate with initial focus in ovarian and endometrial cancers. The company reported preclinical data showing enhanced dual-target binding, improved internalization, superior in vivo efficacy in OVCAR-3 xenografts, and a favorable tolerability profile in cynomolgus monkeys. ArriVent expects to begin a Phase 1 trial and dose the first patient in the second half of 2026.
ArriVent (Nasdaq: AVBP) will present two preclinical posters at the AACR Annual Meeting April 17-22, 2026 in San Diego.
Highlights include structural and preclinical data for the EGFR inhibitor firmonertinib supporting broad activity including exon 20 insertion mutants and high brain penetrance, and preclinical results for dual-target tetravalent ADC ARR-002 (AV-P138-ADC) showing superior efficacy and favorable tolerability in ovarian and endometrial cancer models.
Aarvik Therapeutics (NASDAQ: AVBP) will present two posters and a minisymposium talk at AACR Annual Meeting 2026 in San Diego (April 17–22, 2026). Presentations include data on AV-P138-ADC (ARR-002), the MUTTA™ multispecific ADC platform, and AQUALINK™ exatecan linker-payload innovations.
Poster and minisymposium dates/times: Poster 2660 on April 20 (9 AM–12 PM PT); Minisymposium 6758 on April 21 (2:30–4:30 PM PT); Poster 5757 on April 21 (2–5 PM PT).
ArriVent BioPharma (Nasdaq: AVBP) reported 2025 results and clinical progress. The company ended 2025 with $312.8 million cash and investments, expected to fund operations into 3Q 2027. Key clinical highlights include completed enrollment in the Phase 3 FURVENT study, FDA Breakthrough Therapy designation, China NMPA approval in second-line EGFR exon 20 insertion NSCLC, ongoing pivotal ALPACCA dosing, and ADC lead ARR-217 entering Phase 1 with U.S. IND clearance and first patient dosed. Financials show rising R&D spending and a larger net loss versus 2024.
ArriVent BioPharma (Nasdaq: AVBP) announced on Dec. 22, 2025 that the first patient was dosed in the global pivotal Phase 3 ALPACCA (FURMO-006) study evaluating once-daily oral firmonertinib 240 mg as first-line treatment for EGFR PACC mutant non-small cell lung cancer.
The randomized trial compares firmonertinib to investigator’s choice of osimertinib or afatinib, with primary endpoints of overall response rate (ORR) and progression-free survival (PFS) by blinded independent central review. Dose selection was based on prior data showing 16-month median PFS and a 68% confirmed ORR in the FURTHER trial. The study is designed to support potential accelerated and full regulatory approvals. Estimated annual incidence: ~42,000 global ex-China and ~6,200 US patients.
ArriVent BioPharma (Nasdaq: AVBP) reported Q3 2025 results and clinical progress on Nov 10, 2025. Key clinical milestones include final Phase 1b firmonertinib data in EGFR PACC mutant NSCLC showing meaningful PFS and CNS complete responses, FDA IND clearance for ARR-217 (CDH17-targeted ADC), and planned enrollment for the pivotal ALPACCA Phase 3 in Q4 2025. Topline pivotal data for firmonertinib in EGFR exon 20 insertion NSCLC is projected in early 2026. Financials: $305.4M cash and investments as of Sept 30, 2025, expected to fund operations into mid-2027.
ArriVent BioPharma (Nasdaq: AVBP) has appointed Brent S. Rice as Chief Commercial Officer (CCO). Rice brings over 25 years of experience in the biotechnology and pharmaceutical industry, most recently serving as SVP and global CCO at Autolus Therapeutics.
This strategic hire comes as ArriVent prepares for the potential approval and commercialization of firmonertinib for EGFR mutant non-small cell lung cancer (NSCLC). Rice's experience includes successfully transitioning Autolus from clinical-stage to commercial operations, leading Managed Markets at Juno Therapeutics, and spending 18 years at Amgen in various leadership roles.
ArriVent BioPharma (NASDAQ:AVBP) presented final proof-of-concept data from its global Phase 1b FURTHER trial for firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) at the 2025 World Conference on Lung Cancer. The study demonstrated significant efficacy with 16.0 months median progression-free survival and a 68.2% confirmed overall response rate at 240mg dosing.
Key highlights include 14.6 months median duration of response, confirmed CNS responses with complete responses, and rapid clearance of PACC circulating tumor DNA in 82% of frontline patients at 240mg. The drug showed broad activity across various PACC mutations and maintained a manageable safety profile consistent with EGFR-TKI class drugs. ArriVent plans to initiate the global Phase 3 ALPACCA study in the second half of 2025.
ArriVent BioPharma (NASDAQ:AVBP) reported Q2 2025 financial results and pipeline updates. The company highlighted positive interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC, with plans to initiate the global Phase 3 ALPACCA study in 2H 2025. The company also dosed the first patient in a Phase 1 study of ARR-217, their CDH17-targeted ADC for gastrointestinal tumors.
Financially, ArriVent reported $254.5 million in cash and investments as of June 30, 2025, plus an additional $81.1 million raised in July 2025, extending their runway to mid-2027. The company's net loss increased to $95.8 million for H1 2025, compared to $39.3 million in H1 2024, primarily due to a $40 million upfront payment to Lepu Biopharma.